Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Werner, Ulrich, Haschke, Guido, Herling, Andreas W., Kramer, Werner·2010·Regulatory Peptides

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.regpep.2010.05.008

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 31

  1. Kahn, 2003, The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes, Diabetologia, 46, 3, 10.1007/s00125-002-1009-0 · DOI · Paper page
  2. Brown, 2004, The burden of treatment failure in type 2 diabetes, Diab Care, 27, 1535, 10.2337/diacare.27.7.1535 · DOI · Paper page
  3. Virally, 2007, Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives, Diab Metab, 33, 231, 10.1016/j.diabet.2007.07.001 · DOI
  4. Drucker, 2003, Enhancing incretin action for the treatment of type 2 diabetes, Diab Care, 26, 2929, 10.2337/diacare.26.10.2929 · DOI · Paper page
  5. Holst, 2007, The physiology of glucagon-like peptide 1, Physiol Rev, 87, 1409, 10.1152/physrev.00034.2006 · DOI · Paper page
  6. Kim, 2008, The role of incretins in glucose homeostasis and diabetes treatment, Pharmacol Rev, 60, 470, 10.1124/pr.108.000604 · DOI · Paper page
  7. Vilsbøll, 2001, Reduced postprandial concentrations of intact biologically active glucacon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 · DOI · Paper page
  8. Lugari, 2002, Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes, Horm Metab Res, 34, 150, 10.1055/s-2002-23199 · DOI
  9. Meier, 2008, Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus, Nat Clin Pract Endocrinol Metab, 4, 606, 10.1038/ncpendmet0946 · DOI
  10. Ørskov, 1994, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, 43, 535, 10.2337/diabetes.43.4.535 · DOI
  11. Ørskov, 1988, Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach, Endocrinology, 123, 2009, 10.1210/endo-123-4-2009 · DOI · Paper page
  12. Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37), Nature, 361, 362, 10.1038/361362a0 · DOI · Paper page
  13. Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas, Diabetes, 49, 741, 10.2337/diabetes.49.5.741 · DOI · Paper page
  14. Bulotta, 2002, Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1, J Mol Endocrinol, 29, 347, 10.1677/jme.0.0290347 · DOI
  15. Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas, Pharmacol Ther, 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
  16. Buteau, 2008, GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival, Diab Metab, 34, 73, 10.1016/S1262-3636(08)73398-6 · DOI
  17. Xu, 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
  18. Saraceni, 2007, Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function, Drugs R D, 8, 145, 10.2165/00126839-200708030-00002 · DOI
  19. Mannucci, 2008, Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk, Nutr Metab Cardiovasc Dis, 18, 639, 10.1016/j.numecd.2008.08.002 · DOI
  20. Pi-Sunyer, 2005, Weight loss in type 2 diabetic patients, Diab Care, 28, 1526, 10.2337/diacare.28.6.1526 · DOI
  21. Vanhorebeek, 2007, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J, 28, 88
  22. Deacon, 1995, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects, Diabetes, 44, 1126, 10.2337/diabetes.44.9.1126 · DOI · Paper page
  23. Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, 981
  24. Thorkildsen, 2003, Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice, J Pharmacol Exp Ther, 307, 490, 10.1124/jpet.103.051987 · DOI
  25. Nielsen, 2004, Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes, Regul Pept, 117, 77, 10.1016/j.regpep.2003.10.028 · DOI · Paper page
  26. Tews, 2008, Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues, Horm Metab Res, 40, 172, 10.1055/s-2008-1042426 · DOI
  27. Haschke, 2006, The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats — an isolated perfused pancreas study [Abstract], Diabetologia, 49, 400
  28. Werner, 2008, The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves β-cell function in human pancreatic islets [Abstract], Diabetes, 57, 3
  29. Werner, 2006, Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia [Abstract], Diabetologia, 49, 398
  30. Werner, 2007, The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia [Abstract], Diabetes, 56, 129
  31. Moore, 2007, Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog [Abstract], Diabetologia, 50, S242

Cited by

See all 173

Metadata

Authors
Werner, U., Haschke, G., Herling, A. W., & Kramer, W.
Venue
Regulatory Peptides
Publisher
Elsevier BV
Published
2010-09
Volume
164
Issue
2-3
Pages
58-64
ISSN
0167-0115 (ISSN-L)
OpenAlex
W2095774646
Cited by
173
References
13
FWCI
9.47
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.regpep.2010.05.008
The paper
Werner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010). Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides. https://doi.org/10.1016/j.regpep.2010.05.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.